Our evidence

Our Reviews

Full list:

By subtopic:

Allergic rhinitis (1)
Intranasal corticosteroids for asthma control in people with coexisting asthma and rhinitis
Alpha 1 - antitrypsin deficiency (1)
Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease
Aspergillosis, allergic bronchopulmonary (3)
Azoles for allergic bronchopulmonary aspergillosis associated with asthma
Galactomannan detection for invasive aspergillosis in immunocompromised patients
Galactomannan detection in broncho-alveolar lavage fluid for invasive aspergillosis in immunocompromised patients
Asthma, acute - pharmacotherapy (47)
Anti-bacterial agents (1)
Antibiotics for exacerbations of asthma
Anticholinergics (5)
Anticholinergic therapy for acute asthma in children
Inhaled anticholinergics and short-acting beta-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital
Combined inhaled beta-agonist and anticholinergic agents for emergency management in adults with asthma
Combined inhaled anticholinergics and short-acting beta-agonists for initial treatment of acute asthma in children
Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews
Epinephrine (1)
Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews
Leukotriene antagonists (1)
Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children
Beta-agonists (13)
Addition of intravenous beta2-agonists to inhaled beta2-agonists for acute asthma
Inhaled anticholinergics and short-acting beta-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital
Combined inhaled beta-agonist and anticholinergic agents for emergency management in adults with asthma
Combined inhaled anticholinergics and short-acting beta-agonists for initial treatment of acute asthma in children
Commercial versus home-made spacers in delivering bronchodilator therapy for acute therapy in children
Continuous versus intermittent beta-agonists for acute asthma
Addition of intravenous aminophylline to inhaled beta2-agonists in adults with acute asthma
Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Inhaled beta2-agonists for asthma in mechanically ventilated patients
Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews
Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators
Intravenous beta2-agonists versus intravenous aminophylline for acute asthma
Intravenous beta2-agonists for acute asthma in the emergency department
Inhaler devices and delivery therapy (5)
Commercial versus home-made spacers in delivering bronchodilator therapy for acute therapy in children
Heliox for non-intubated acute asthma patients
Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Inhaled beta2-agonists for asthma in mechanically ventilated patients
Interventions to improve inhaler technique for people with asthma
Magnesium sulfate (5)
Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department
Intravenous magnesium sulfate for treating children with acute asthma in the emergency department
Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews
Inhaled magnesium sulfate in the treatment of acute asthma
Magnesium sulfate for treating exacerbations of acute asthma in the emergency department
Other bronchodilators (2)
Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews
Ketamine for management of acute exacerbations of asthma in children
Steroids, inhaled (4)
Early use of inhaled corticosteroids in the emergency department treatment of acute asthma
Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children
Inhaled steroids for acute asthma following emergency department discharge
Interventions to improve adherence to inhaled steroids for asthma
Steroids, oral and systemic (7)
Corticosteroids for acute severe asthma in hospitalised patients
Corticosteroids for hospitalised children with acute asthma
Corticosteroids for preventing relapse following acute exacerbations of asthma
Different oral corticosteroid regimens for acute asthma
Early emergency department treatment of acute asthma with systemic corticosteroids
Intramuscular versus oral corticosteroids to reduce relapses following discharge from the emergency department for acute asthma
Patient- and parent-initiated oral steroids for asthma exacerbations
Xanthines (3)
Addition of intravenous aminophylline to inhaled beta2-agonists in adults with acute asthma
Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators
Intravenous beta2-agonists versus intravenous aminophylline for acute asthma
Asthma, acute - non-pharmacotherapy (8)
Delivery of care (0)
Monitoring (2)
Pulse oximeters to self monitor oxygen saturation levels as part of a personalised asthma action plan for people with asthma
Personalised asthma action plans for adults with asthma
Ventilation (3)
Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews
Non-invasive positive pressure ventilation for acute asthma in children
Non-invasive positive pressure ventilation for treatment of respiratory failure due to severe acute exacerbations of asthma
Education (3)
Asthma education for school staff
Education interventions for adults who attend the emergency room for acute asthma
Interventions for educating children who are at risk of asthma-related emergency department attendance
Asthma, chronic - pharmacotherapy (173)
Adverse effects of treatment (6)
Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events
Regular treatment with formoterol for chronic asthma: serious adverse events
Regular treatment with salmeterol for chronic asthma: serious adverse events
Inhaled steroids with and without regular salmeterol for asthma: serious adverse events
Inhaled steroids with and without regular formoterol for asthma: serious adverse events
Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events
Anti-inflammatory agents, non-steroidal (1)
Macrolides versus placebo for chronic asthma
Antibodies, monoclonal (4)
Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for people with asthma
Anti-IL5 therapies for asthma
Omalizumab for asthma in adults and children
Subcutaneous omalizumab for people with asthma (protocol stage)
Beta-agonists, long-acting (29)
Addition of long-acting beta2 agonists or long-acting muscarinic antagonists versus doubling the dose of inhaled corticosteroids (ICS) in adolescents and adults with uncontrolled asthma with medium dose ICS: a systematic review and network meta-analysis (protocol stage)
Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children
Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma
Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events
Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma
Regular treatment with formoterol for chronic asthma: serious adverse events
Regular treatment with salmeterol for chronic asthma: serious adverse events
Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying doses of inhaled corticosteroids in adolescents and adults with asthma: a systematic review and network meta-analysis (protocol stage)
Addition to inhaled corticosteroids of long-acting beta-agonists versus anti-leukotrienes for chronic asthma
Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children
Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma
Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children
Inhaled steroids with and without regular salmeterol for asthma: serious adverse events
Long-acting beta2-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults and children
Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid
Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children
Long-acting beta2-agonists versus theophylline for maintenance treatment of asthma
Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews
Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews
Inhaled steroids with and without regular formoterol for asthma: serious adverse events
Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events
Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma
Stopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroids
Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma
Addition of long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children
Vilanterol and fluticasone furoate for asthma
Stopping long-acting beta-agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids
Beta-agonists, short-acting (8)
Beta-agonists for exercise-induced asthma
Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children
Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma
Inhaled short acting beta2-agonist use in chronic asthma: regular versus as needed treatment
Pressurised metered dose inhalers versus all other hand-held inhaler devices to deliver beta-2 agonist bronchodilators for non-acute asthma
Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma
Short acting beta2-agonists for recurrent wheeze in children under two years of age
Management in pregnancy (1)
Interventions for managing asthma in pregnancy
Muscarinic antagonists (5)
Addition of long-acting beta2 agonists or long-acting muscarinic antagonists versus doubling the dose of inhaled corticosteroids (ICS) in adolescents and adults with uncontrolled asthma with medium dose ICS: a systematic review and network meta-analysis (protocol stage)
Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma
Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma
Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma
Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta-agonists (LABA) for adults with asthma
Other (1)
Mast-cell stabilising agents to prevent exercise-induced bronchoconstriction
Phosphodiesterases (0)
Statins (1)
Statins for asthma
Steroids, inhaled (51)
Addition of long-acting beta2 agonists or long-acting muscarinic antagonists versus doubling the dose of inhaled corticosteroids (ICS) in adolescents and adults with uncontrolled asthma with medium dose ICS: a systematic review and network meta-analysis (protocol stage)
Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children
Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children
Beclomethasone at different doses for chronic asthma
Budesonide at different doses for chronic asthma
Budesonide versus placebo for chronic asthma in children and adults
Intermittent inhaled corticosteroid therapy versus placebo for persistent asthma in children and adults
Ciclesonide versus other inhaled steroids for chronic asthma in children and adults
Ciclesonide versus placebo for chronic asthma in adults and children
Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma
Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
Inhaled corticosteroids in children with persistent asthma: effects on growth
Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events
Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma
Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma
Inhaled corticosteroids in children with persistent asthma: dose-response effects on growth
Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying doses of inhaled corticosteroids in adolescents and adults with asthma: a systematic review and network meta-analysis (protocol stage)
Fluticasone at different doses for chronic asthma in adults and children
Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children
Fluticasone versus placebo for chronic asthma in adults and children
Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children
Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma
Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children
Holding chambers versus nebulisers for inhaled steroids in chronic asthma
Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children
Beclomethasone versus placebo for chronic asthma
Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease
Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma
Fluticasone versus 'extrafine' HFA-beclomethasone dipropionate for chronic asthma in adults and children
Inhaled steroids for episodic viral wheeze of childhood
Inhaled steroids with and without regular salmeterol for asthma: serious adverse events
Inhaled versus oral steroids for adults with chronic asthma
Addition of anti-leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma
Addition of anti-leukotriene agents to inhaled corticosteroids in children with persistent asthma
Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta-agonists (LABA) for adults with asthma
Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults
Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children
Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews
Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews
Inhaled steroids with and without regular formoterol for asthma: serious adverse events
Stepping down the dose of inhaled corticosteroids for adults with asthma
Stopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroids
Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma
Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma
Addition of long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children
Beclomethasone for asthma in children: effects on linear growth
Beclomethasone versus budesonide for chronic asthma
Vilanterol and fluticasone furoate for asthma
Stopping long-acting beta-agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids
Inhaled corticosteroids in children with persistent asthma: effects of different drugs and delivery devices on growth
Steroids, oral (3)
Inhaled steroids for episodic viral wheeze of childhood
Inhaled versus oral steroids for adults with chronic asthma
Parent-initiated oral corticosteroid therapy for intermittent wheezing illnesses in children
Steroids, intranasal (1)
Intranasal corticosteroids for asthma control in people with coexisting asthma and rhinitis
Combination and additive therapies (25)
Addition of long-acting beta2 agonists or long-acting muscarinic antagonists versus doubling the dose of inhaled corticosteroids (ICS) in adolescents and adults with uncontrolled asthma with medium dose ICS: a systematic review and network meta-analysis (protocol stage)
Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children
Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma
Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events
Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma
Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma
Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying doses of inhaled corticosteroids in adolescents and adults with asthma: a systematic review and network meta-analysis (protocol stage)
Addition to inhaled corticosteroids of long-acting beta-agonists versus anti-leukotrienes for chronic asthma
Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children
Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma
Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children
Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children
Inhaled steroids with and without regular salmeterol for asthma: serious adverse events
Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta-agonists (LABA) for adults with asthma
Ketotifen alone or as additional medication for long-term control of asthma and wheeze in children
Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children
Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews
Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews
Inhaled steroids with and without regular formoterol for asthma: serious adverse events
Stopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroids
Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma
Addition of long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children
Vilanterol and fluticasone furoate for asthma
Stopping long-acting beta-agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids
Anti-bacterial agents (1)
Macrolides versus placebo for chronic asthma
Antihistamines (1)
Ketotifen alone or as additional medication for long-term control of asthma and wheeze in children
Allergen immunotherapy (2)
Injection allergen immunotherapy for asthma
Sublingual immunotherapy for asthma
Anticholinergics (3)
Anticholinergic agents for chronic asthma in adults
Anticholinergic drugs for wheeze in children under the age of two years
Anticholinergic therapy for chronic asthma in children over two years of age
Cardioselective beta-blockers (1)
Cardioselective beta-blockers for reversible airway disease
Cromones (5)
Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma
Nedocromil sodium for chronic asthma in children
Nedocromil sodium for preventing exercise-induced bronchoconstriction
Nedocromil sodium versus sodium cromoglycate for preventing exercise-induced bronchoconstriction
Inhaled sodium cromoglycate for asthma in children
Gastro-oesophogeal reflux treatment (1)
Pharmacological and surgical interventions for the treatment of gastro-oesophageal reflux in adults and children with asthma
Histamine antagonists (1)
Oxatomide for stable asthma in adults and children
Inhaler devices and delivery of therapy (2)
Holding chambers versus nebulisers for inhaled steroids in chronic asthma
Pressurised metered dose inhalers versus all other hand-held inhaler devices to deliver beta-2 agonist bronchodilators for non-acute asthma
Leukotriene antagonists (6)
Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children
Addition to inhaled corticosteroids of long-acting beta-agonists versus anti-leukotrienes for chronic asthma
Addition of anti-leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma
Addition of anti-leukotriene agents to inhaled corticosteroids in children with persistent asthma
Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma
Leukotriene receptor antagonists as maintenance and intermittent therapy for episodic viral wheeze in children
Steroid sparing agents (10)
Azathioprine as an oral corticosteroid sparing agent for asthma
Chloroquine as a steroid sparing agent for asthma
Colchicine as an oral corticosteroid sparing agent for asthma
Cyclosporin as an oral corticosteroid sparing agent in stable asthma
Dapsone as an oral corticosteroid sparing agent for asthma
Gold as an oral corticosteroid sparing agent in stable asthma
Long-acting beta2-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults and children
Methotrexate as a steroid sparing agent for asthma in adults
Omalizumab for asthma in adults and children
Troleandomycin as an oral corticosteroid sparing agent in stable asthma
Vaccines (2)
Pneumococcal vaccine for asthma
Vaccines for preventing influenza in people with asthma
Xanthines (2)
Long-acting beta2-agonists versus theophylline for maintenance treatment of asthma
Oral xanthines as maintenance treatment for asthma in children
Asthma, chronic - non-pharmacotherapy (95)
Biomarkers (3)
Exhaled nitric oxide levels to guide treatment for children with asthma
Exhaled nitric oxide levels to guide treatment for adults with asthma
Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults
Complementary therapies (7)
Acupuncture for chronic asthma
Herbal interventions for chronic asthma in adults and children
Homeopathy for chronic asthma
Ionisers for chronic asthma
Manual therapy for asthma
Speleotherapy for asthma
Yoga for asthma
Delivery of care (7)
Shared decision-making for people with asthma
Smartphone and tablet self management apps for asthma
Chronic disease management for asthma
Indigenous healthcare worker involvement for Indigenous adults and children with asthma
Nurse versus physician-led care for the management of asthma
Primary care based clinics for asthma
Lay-led and peer support interventions for adolescents with asthma
Diet therapy and nutrition support (14)
Calorie controlled diet for chronic asthma
Dietary marine fatty acids (fish oil) for asthma in adults and children
Weight loss interventions for chronic asthma
Dietary sodium manipulation and asthma
Herbal interventions for chronic asthma in adults and children
Mono and multifaceted inhalant and/or food allergen reduction interventions for preventing asthma in children at high risk of developing asthma
Monosodium glutamate avoidance for chronic asthma in adults and children
Selenium supplementation for asthma
Tartrazine exclusion for allergic asthma
Caffeine for asthma
Vitamin C for asthma and exercise-induced bronchoconstriction
Vitamin D supplementation in pregnant or breastfeeding women or young children for preventing asthma (protocol stage)
Vitamin D for the management of asthma
Vitamins C and E for asthma and exercise-induced bronchoconstriction
Disease management and monitoring (26)
Remote versus face-to-face check-ups for asthma
Exhaled nitric oxide levels to guide treatment for children with asthma
Shared decision-making for people with asthma
Smartphone and tablet self management apps for asthma
Chronic disease management for asthma
Culture-specific programs for children and adults from minority groups who have asthma
Dehumidifiers for chronic asthma
Digital interventions to improve adherence to maintenance medication in asthma
Weight loss interventions for chronic asthma
House dust mite control measures for asthma
Exhaled nitric oxide levels to guide treatment for adults with asthma
Feather versus non-feather bedding for asthma
Home-based educational interventions for children with asthma
Indigenous healthcare worker involvement for Indigenous adults and children with asthma
Ionisers for chronic asthma
Mono and multifaceted inhalant and/or food allergen reduction interventions for preventing asthma in children at high risk of developing asthma
Options for self-management education for adults with asthma
Pet allergen control measures for allergic asthma in children and adults
Self-management education and regular practitioner review for adults with asthma
Lay-led and peer support interventions for adolescents with asthma
Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults
Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults
Telehealthcare for asthma
Written action plans for asthma in children
Home telemonitoring and remote feedback between clinic visits for asthma
Personalised asthma action plans for adults with asthma
Education (15)
School-based self-management interventions for asthma in children and adolescents: a mixed methods systematic review
Remote versus face-to-face check-ups for asthma
Asthma education for school staff
Caseworker-assigned discharge plans to prevent hospital readmission for acute exacerbations in children with chronic respiratory illness
Culture-specific programs for children and adults from minority groups who have asthma
Education interventions for adults who attend the emergency room for acute asthma
Educational interventions for asthma in children
Home-based educational interventions for children with asthma
Limited (information only) patient education programs for adults with asthma
Options for self-management education for adults with asthma
Pulmonary rehabilitation for adults with asthma (protocol stage)
Self-management education and regular practitioner review for adults with asthma
Lay-led and peer support interventions for adolescents with asthma
Home telemonitoring and remote feedback between clinic visits for asthma
Interventions for educating children who are at risk of asthma-related emergency department attendance
Environment exposure reduction (1)
Individual-level interventions to reduce personal exposure to outdoor air pollution and their effects on people with long-term respiratory conditions
Invasive therapeutic procedures (1)
Bronchial thermoplasty for moderate or severe persistent asthma in adults
Management in pregnancy (1)
Interventions for managing asthma in pregnancy
Psychotherapy (7)
Cognitive behavioural therapy (CBT) for adults and adolescents with asthma
Family therapy for asthma in children
Health psychology interventions to improve adherence to maintenance therapies in asthma (protocol stage)
Psychological interventions for adults with asthma
Psychological interventions for asthma in children and adolescents (protocol stage)
Psychological interventions for children with asthma
Written emotional disclosure for asthma
Physical therapy (11)
Alexander technique for chronic asthma
Breathing exercises for adults with asthma
Breathing exercises for children with asthma
Weight loss interventions for chronic asthma
Inspiratory muscle training for asthma
Water-based exercise for adults with asthma
Manual therapy for asthma
Physical training for asthma
Pulmonary rehabilitation for adults with asthma (protocol stage)
Swimming training for asthma in children and adolescents aged 18 years and under
Yoga for asthma
Pulmonary rehabilitation (2)
Telerehabilitation for chronic respiratory disease
Pulmonary rehabilitation for adults with asthma (protocol stage)
Asthma, occupational (1)
Workplace interventions to deal with occupational asthma
Asthma, primary prevention (3)
Interventions for autumn exacerbations of asthma in children
Interventions to improve adherence to inhaled steroids for asthma
Interventions to improve inhaler technique for people with asthma
Breathing dysregulation/hyperventilation syndrome (2)
Breathing exercises for dysfunctional breathing/hyperventilation syndrome in adults
Breathing exercises for dysfunctional breathing/hyperventilation syndrome in children
Bronchiectasis (46)
Anti inflammatory agents, non-steroidal (3)
Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis
Interventions for bronchiectasis: an overview of Cochrane systematic reviews
Oral non steroid anti-inflammatories for children and adults with bronchiectasis
Anti-bacterial agents (9)
Continuous versus intermittent antibiotics for bronchiectasis
Dual antibiotics for bronchiectasis
Head-to-head trials of antibiotics for bronchiectasis
Interventions for bronchiectasis: an overview of Cochrane systematic reviews
Intermittent prophylactic antibiotics for bronchiectasis
Macrolide antibiotics for bronchiectasis
Oral versus inhaled antibiotics for bronchiectasis
Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults
Short courses of antibiotics for children and adults with bronchiectasis
Anticholinergics (2)
Interventions for bronchiectasis: an overview of Cochrane systematic reviews
Anticholinergic therapy for bronchiectasis
Beta-agonists (4)
Combination inhaled corticosteroids and long-acting beta-agonists for children and adults with bronchiectasis
Interventions for bronchiectasis: an overview of Cochrane systematic reviews
Long-acting beta2-agonists for bronchiectasis
Short acting beta2-agonists for bronchiectasis
Delivery of care (4)
Interventions for enhancing adherence to treatment in adults with bronchiectasis
Interventions for bronchiectasis: an overview of Cochrane systematic reviews
Nurse-led versus doctor-led care for bronchiectasis
Self-management for bronchiectasis
Environment exposure reduction (1)
Individual-level interventions to reduce personal exposure to outdoor air pollution and their effects on people with long-term respiratory conditions
Leukotriene antagonists (2)
Interventions for bronchiectasis: an overview of Cochrane systematic reviews
Leukotriene receptor antagonists for non-cystic fibrosis bronchiectasis
Mucoactive agents (3)
Inhaled hyperosmolar agents for bronchiectasis
Interventions for bronchiectasis: an overview of Cochrane systematic reviews
Mucolytics for bronchiectasis
Physical therapy (6)
Airway clearance techniques for bronchiectasis
Physical training for bronchiectasis
Exercise training for bronchiectasis
Interventions for bronchiectasis: an overview of Cochrane systematic reviews
Positive expiratory pressure therapy versus other airway clearance techniques for bronchiectasis
Singing for children and adults with bronchiectasis
Pulmonary rehabilitation (1)
Telerehabilitation for chronic respiratory disease
Statins (0)
Steroids (4)
Combination inhaled corticosteroids and long-acting beta-agonists for children and adults with bronchiectasis
Interventions for bronchiectasis: an overview of Cochrane systematic reviews
Oral corticosteroids for bronchiectasis (stable and acute exacerbations)
Inhaled corticosteroids for bronchiectasis
Surgery (2)
Interventions for bronchiectasis: an overview of Cochrane systematic reviews
Surgery versus non-surgical treatment for bronchiectasis
Vaccines (3)
Influenza vaccine for children and adults with bronchiectasis
Interventions for bronchiectasis: an overview of Cochrane systematic reviews
Pneumococcal vaccines for children and adults with bronchiectasis
Xanthines (2)
Interventions for bronchiectasis: an overview of Cochrane systematic reviews
Oral methylxanthines for bronchiectasis
Bronchoconstriction, exercise-induced (7)
Beta-agonists for exercise-induced asthma
Inhaled corticosteroids compared to placebo for prevention of exercise induced bronchoconstriction
Mast-cell stabilising agents to prevent exercise-induced bronchoconstriction
Nedocromil sodium for preventing exercise-induced bronchoconstriction
Nedocromil sodium versus sodium cromoglycate for preventing exercise-induced bronchoconstriction
Vitamin C for asthma and exercise-induced bronchoconstriction
Vitamins C and E for asthma and exercise-induced bronchoconstriction
Chronic obstructive pulmonary disease, stable - pharmacotherapy (102)
Adverse effects of treatments (1)
Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
Antibodies, monoclonal (1)
Anti-IL-5 therapies for chronic obstructive pulmonary disease
Immunostimulants (1)
Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease (protocol stage)
Muscarinic antagonists (18)
Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD)
Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD)
Combination inhaled steroid and long-acting beta-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease
Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease
Aclidinium bromide for stable chronic obstructive pulmonary disease
Long-acting beta-agonist in addition to tiotropium versus either tiotropium or long-acting beta-agonist alone for chronic obstructive pulmonary disease
Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease
Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease
Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease
Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease
Pressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary disease
The effect of adding inhaled corticosteroids to tiotropium and long-acting beta2-agonists for chronic obstructive pulmonary disease
Tiotropium versus placebo for chronic obstructive pulmonary disease
Tiotropium for stable chronic obstructive pulmonary disease
Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease
Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease
Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)
Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis
Beta-agonists, long-acting, twice daily (22)
Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD)
Combination inhaled steroid and long-acting beta-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease
Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD
Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease
Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease
Inhaled corticosteroids versus long-acting beta-agonists for chronic obstructive pulmonary disease
Combined corticosteroid and long-acting beta2-agonist in one inhaler versus long-acting beta2-agonists for chronic obstructive pulmonary disease
Aclidinium bromide for stable chronic obstructive pulmonary disease
Long-acting beta-agonist in addition to tiotropium versus either tiotropium or long-acting beta-agonist alone for chronic obstructive pulmonary disease
Inhaled corticosteroids with combination inhaled long-acting beta-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease
Indacaterol, a once-daily beta-agonist, versus twice-daily beta-agonists or placebo for chronic obstructive pulmonary disease
Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease
Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease
Long-acting beta-agonists for chronic obstructive pulmonary disease
Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease
Once-daily LABA/ICS combined inhalers versus inhaled long-acting beta2-agonists for people with chronic obstructive pulmonary disease (protocol stage)
Pressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary disease
The effect of adding inhaled corticosteroids to tiotropium and long-acting beta2-agonists for chronic obstructive pulmonary disease
Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease
Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)
Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis
Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis
Beta-agonists, short-acting (4)
Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD
Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease
Pressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary disease
Short-acting beta2-agonists for stable chronic obstructive pulmonary disease
Beta-agonists, long-acting, once daily (6)
Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD
Indacaterol, a once-daily beta-agonist, versus twice-daily beta-agonists or placebo for chronic obstructive pulmonary disease
Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease
Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)
Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis
Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis
Proton pump inhibitors (1)
Proton pump inhibitors for chronic obstructive pulmonary disease
Sexual dysfunction (1)
Interventions for sexual dysfunction in people with chronic obstructive pulmonary disease (COPD)
Statins (1)
Statins versus placebo for people with chronic obstructive pulmonary disease
Steroids, inhaled (16)
Combination inhaled steroid and long-acting beta-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease
Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease
Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease
Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease
Inhaled corticosteroids versus long-acting beta-agonists for chronic obstructive pulmonary disease
Combined corticosteroid and long-acting beta2-agonist in one inhaler versus long-acting beta2-agonists for chronic obstructive pulmonary disease
Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
Inhaled corticosteroids with combination inhaled long-acting beta-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease
Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease
Inhaled corticosteroids for stable chronic obstructive pulmonary disease
Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease
Once-daily LABA/ICS combined inhalers versus inhaled long-acting beta2-agonists for people with chronic obstructive pulmonary disease (protocol stage)
The effect of adding inhaled corticosteroids to tiotropium and long-acting beta2-agonists for chronic obstructive pulmonary disease
Beclometasone for chronic obstructive pulmonary disease
Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)
Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis
Steroids, oral (1)
Oral corticosteroids for stable chronic obstructive pulmonary disease
Combination and additive therapies (15)
Combination inhaled steroid and long-acting beta-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease
Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease
Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease
Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease
Combined corticosteroid and long-acting beta2-agonist in one inhaler versus long-acting beta2-agonists for chronic obstructive pulmonary disease
Long-acting beta-agonist in addition to tiotropium versus either tiotropium or long-acting beta-agonist alone for chronic obstructive pulmonary disease
Inhaled corticosteroids with combination inhaled long-acting beta-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease
Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease
Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease
Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease
Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease
Once-daily LABA/ICS combined inhalers versus inhaled long-acting beta2-agonists for people with chronic obstructive pulmonary disease (protocol stage)
The effect of adding inhaled corticosteroids to tiotropium and long-acting beta2-agonists for chronic obstructive pulmonary disease
Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis
Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis
Cardioselective beta-blockers (1)
Cardioselective beta-blockers for chronic obstructive pulmonary disease
Mucolytic agents (1)
Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease
Phosphodiesterases (1)
Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease
Anti-bacterial agents (4)
Antibiotics for exacerbations of chronic obstructive pulmonary disease
Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)
Head-to-head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease
Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis
Vaccines (2)
Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease
Influenza vaccine for chronic obstructive pulmonary disease (COPD)
Delivery of inhaled therapy (2)
Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD
Pressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary disease
Xanthines (3)
Methylxanthines for exacerbations of chronic obstructive pulmonary disease
Oral theophylline for chronic obstructive pulmonary disease
Oral xanthine derivatives (theophylline and doxofylline) for patients with stable chronic obstructive pulmonary disease (COPD) (protocol stage)
Chronic obstructive pulmonary disease, stable - non-pharmacotherapy (63)
Advance care planning (0)
Complementary therapies (3)
Active mind-body movement therapies as an adjunct to or in comparison with pulmonary rehabilitation for people with chronic obstructive pulmonary disease
Upper limb exercise training for COPD
Tai Chi for chronic obstructive pulmonary disease (COPD)
Delivery of care (10)
Tailored or adapted interventions for adults with chronic obstructive pulmonary disease and at least one other long-term condition: a mixed methods review
Digital interventions for the management of chronic obstructive pulmonary disease
Home care by outreach nursing for chronic obstructive pulmonary disease
Telerehabilitation for chronic respiratory disease
Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Interventions to promote referral, uptake and adherence to pulmonary rehabilitation for people with chronic obstructive pulmonary disease (COPD) (protocol stage)
Pulmonary rehabilitation for chronic obstructive pulmonary disease
Pulmonary rehabilitation using minimal equipment for people with chronic obstructive pulmonary disease (protocol stage)
Telehealth interventions: remote monitoring and consultations for people with chronic obstructive pulmonary disease (COPD)
Interventions for promoting physical activity in people with chronic obstructive pulmonary disease (COPD)
Diet therapy and nutritional support (2)
Nutritional supplementation for stable chronic obstructive pulmonary disease
Vitamin D for the management of chronic obstructive pulmonary disease (protocol stage)
Education and disease management (10)
Digital interventions for the management of chronic obstructive pulmonary disease
Educational interventions for health professionals managing chronic obstructive pulmonary disease in primary care
Integrated disease management interventions for patients with chronic obstructive pulmonary disease
Interventions to improve inhaler technique for adults with chronic obstructive pulmonary disease (protocol stage)
Self-management interventions for people with chronic obstructive pulmonary disease
Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease
Computer and mobile technology interventions for self-management in chronic obstructive pulmonary disease
Telehealth interventions: remote monitoring and consultations for people with chronic obstructive pulmonary disease (COPD)
Telehealthcare for chronic obstructive pulmonary disease
Interventions to improve adherence to pharmacological therapy for chronic obstructive pulmonary disease (COPD)
Environment exposure reduction (1)
Individual-level interventions to reduce personal exposure to outdoor air pollution and their effects on people with long-term respiratory conditions
Oxygen therapy and ventilation (7)
Non-invasive ventilation during exercise training for people with chronic obstructive pulmonary disease
Domiciliary oxygen for chronic obstructive pulmonary disease
Chronic non-invasive ventilation for chronic obstructive pulmonary disease
Oxygen therapy during exercise training in chronic obstructive pulmonary disease
Oxygen for breathlessness in patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy
Ambulatory oxygen for people with chronic obstructive pulmonary disease who are not hypoxaemic at rest
Short-term ambulatory oxygen for chronic obstructive pulmonary disease
Palliative care (0)
Physical therapy (16)
Active mind-body movement therapies as an adjunct to or in comparison with pulmonary rehabilitation for people with chronic obstructive pulmonary disease
Airway clearance techniques for chronic obstructive pulmonary disease
Upper limb exercise training for COPD
Breathing exercises for chronic obstructive pulmonary disease
Non-invasive ventilation during exercise training for people with chronic obstructive pulmonary disease
Inspiratory muscle training, with or without concomitant pulmonary rehabilitation, for chronic obstructive pulmonary disease (COPD) (protocol stage)
Optimal intensity and type of leg exercise training for people with chronic obstructive pulmonary disease
Interventions to promote referral, uptake and adherence to pulmonary rehabilitation for people with chronic obstructive pulmonary disease (COPD) (protocol stage)
Supervised maintenance programmes following pulmonary rehabilitation compared to usual care for chronic obstructive pulmonary disease
Neuromuscular electrostimulation for adults with chronic obstructive pulmonary disease
Oxygen therapy during exercise training in chronic obstructive pulmonary disease
Pulmonary rehabilitation for chronic obstructive pulmonary disease
Pulmonary rehabilitation using minimal equipment for people with chronic obstructive pulmonary disease (protocol stage)
Tai Chi for chronic obstructive pulmonary disease (COPD)
Water-based exercise training for chronic obstructive pulmonary disease
Interventions for promoting physical activity in people with chronic obstructive pulmonary disease (COPD)
Psychotherapy (1)
Cognitive behavioural approaches for managing dyspnoea in people with chronic obstructive pulmonary disease (COPD) (protocol stage)
Pulmonary rehabilitation (8)
Factors influencing referral to and uptake and attendance of pulmonary rehabilitation for chronic obstructive pulmonary disease: a qualitative evidence synthesis of the experiences of service users, their families, and healthcare providers (protocol stage)
Telerehabilitation for chronic respiratory disease
Inspiratory muscle training, with or without concomitant pulmonary rehabilitation, for chronic obstructive pulmonary disease (COPD) (protocol stage)
Interventions to promote referral, uptake and adherence to pulmonary rehabilitation for people with chronic obstructive pulmonary disease (COPD) (protocol stage)
Supervised maintenance programmes following pulmonary rehabilitation compared to usual care for chronic obstructive pulmonary disease
Pulmonary rehabilitation for chronic obstructive pulmonary disease
Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease
Pulmonary rehabilitation using minimal equipment for people with chronic obstructive pulmonary disease (protocol stage)
Sexual dysfunction (1)
Interventions for sexual dysfunction in people with chronic obstructive pulmonary disease (COPD)
Smoking cessation (2)
Smoking cessation for chronic obstructive pulmonary disease
Smoking cessation for people with chronic obstructive pulmonary disease
Surgery (2)
Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease
Lung volume reduction surgery for diffuse emphysema
Chronic obstructive pulmonary disease, exacerbations (25)
Anti-bacterial agents (1)
Biomarkers to guide antibiotic therapy for COPD exacerbations (protocol stage)
Anticholinergics (3)
Anticholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease
Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD
Inhaled short-acting beta2-agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease
Beta-agonists (4)
Anticholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease
Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD
Inhaled short-acting beta2-agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease
Methylxanthines for exacerbations of chronic obstructive pulmonary disease
Biomarkers (1)
Biomarkers to guide antibiotic therapy for COPD exacerbations (protocol stage)
Education and disease management (2)
Action plans with brief patient education for exacerbations in chronic obstructive pulmonary disease
Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease
Magnesium sulfate (1)
Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease
Steroids (2)
Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease
Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease
Pulmonary rehabilitation (2)
Interventions to promote referral, uptake and adherence to pulmonary rehabilitation for people with chronic obstructive pulmonary disease (COPD) (protocol stage)
Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease
Oxygen therapy and ventilation (3)
Heliox for treatment of exacerbations of chronic obstructive pulmonary disease
Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease
Oxygen therapy in the pre-hospital setting for acute exacerbations of chronic obstructive pulmonary disease
Delivery of care (2)
Hospital at home for acute exacerbations of chronic obstructive pulmonary disease
Interventions to promote referral, uptake and adherence to pulmonary rehabilitation for people with chronic obstructive pulmonary disease (COPD) (protocol stage)
Other (4)
Antibiotics for exacerbations of chronic obstructive pulmonary disease
Carbonic anhydrase inhibitors for hypercapnic ventilatory failure in chronic obstructive pulmonary disease
Doxapram for ventilatory failure due to exacerbations of chronic obstructive pulmonary disease
Singing for adults with chronic obstructive pulmonary disease
Cough, chronic (18)
Anti-bacterial agents (2)
Antibiotics for persistent cough or wheeze following acute bronchiolitis in children
Antibiotics for prolonged wet cough in children
Anticholinergics (1)
Anticholinergics for prolonged non-specific cough in children
Antihistamines (1)
Anti-histamines for prolonged non-specific cough in children
Beta-agonists (1)
Inhaled beta2-agonists for non-specific chronic cough in children
Cromones (1)
Inhaled cromones for prolonged non-specific cough in children
Delivery of care (1)
Clinical pathways for chronic cough in children
Environmental remediation and allergen reduction (1)
Indoor air modification interventions for prolonged non-specific cough in children
Gastro-oesophageal reflux treatment (1)
Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults
Leukotriene antagonists (1)
Leukotriene receptor antagonist for prolonged non-specific cough in children
Speech and language therapy (1)
Speech and language therapy for management of chronic cough
Steroids (3)
Inhaled corticosteroids for subacute and chronic cough in adults
Inhaled corticosteroids for subacute cough in children
Inhaled corticosteroids for non-specific chronic cough in children
Topical treatment (2)
Codeine versus placebo for chronic cough in children
Honey and lozenges for children with non-specific cough
Treatment of sleep apnea (1)
Treatment of obstructive sleep apnoea for chronic cough in children
Xanthines (1)
Methylxanthines for prolonged non-specific cough in children
Cough, post-viral (1)
Antibiotics for persistent cough or wheeze following acute bronchiolitis in children
Cough, subacute (2)
Inhaled corticosteroids for subacute and chronic cough in adults
Inhaled corticosteroids for subacute cough in children
Diagnostic test accuracy (1)
Galactomannan detection for invasive aspergillosis in immunocompromised patients
Hypertension, pulmonary (10)
Anticoagulation therapy versus placebo for pulmonary hypertension
Calcium channel blockers for pulmonary arterial hypertension
Doppler trans-thoracic echocardiography for detection of pulmonary hypertension in adults
Endothelin receptor antagonists for pulmonary arterial hypertension
Exercise-based rehabilitation programmes for pulmonary hypertension
Phosphodiesterase 5 inhibitors for pulmonary hypertension
Phosphodiesterase 5 inhibitors for pulmonary hypertension
Prostacyclin for pulmonary hypertension in adults
Prostacyclin for pulmonary arterial hypertension
Guanylate cyclase stimulators for pulmonary hypertension
Idiopathic pulmonary fibrosis (5)
Antifibrotic therapies for idiopathic pulmonary fibrosis (protocol stage)
Corticosteroids for idiopathic pulmonary fibrosis
Telerehabilitation for chronic respiratory disease
Non-steroid agents for idiopathic pulmonary fibrosis
Prognosis of adults with idiopathic pulmonary fibrosis without treatment or without effective therapies (protocol stage)
Lung disease, aspiration (1)
Restriction of oral intake of water for aspiration lung disease in children
Lung diseases, interstitial (6)
Cyclophosphamide for connective tissue disease–associated interstitial lung disease
Domiciliary oxygen for interstitial lung disease
Telerehabilitation for chronic respiratory disease
Nebulised morphine for severe interstitial lung disease
Pulmonary rehabilitation for interstitial lung disease
Ambulatory and short-burst oxygen for interstitial lung disease
Obesity hypoventilation syndrome (0)
Pleural diseases (1)
Intra-pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult parapneumonic effusions and empyema
Respiratory morbidity associated with long-term conditions (2)
Antibiotics for chronic pulmonary infection in children with a neurodisability (neurodevelopmental disorder) (protocol stage)
Non-pharmaceutical management of respiratory morbidity in children with severe global developmental delay
Sarcoidosis, pulmonary (2)
Corticosteroids for pulmonary sarcoidosis
Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis
Sleep apnoea, central (2)
Non-invasive positive pressure ventilation for central sleep apnoea in adults (protocol stage)
Pharmacological treatment for central sleep apnoea in adults (protocol stage)
Sleep apnoea, obstructive (24)
Continuous positive airways pressure (6)
Continuous positive airway pressure delivery interfaces for obstructive sleep apnoea
Continuous positive airways pressure for obstructive sleep apnoea in adults
Educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines in adults with obstructive sleep apnoea
Pressure modification or humidification for improving usage of continuous positive airway pressure machines in adults with obstructive sleep apnoea
Non-invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea
Oral appliances for obstructive sleep apnoea (protocol stage)
Diagnosis (1)
Clinical utility of limited channel sleep studies versus polysomnography for obstructive sleep apnoea (protocol stage)
Oral appliance therapy (2)
Oral appliances for obstructive sleep apnoea (protocol stage)
Oral appliances for obstructive sleep apnoea
Drug treatment (4)
Anti-inflammatory medications for obstructive sleep apnoea in children
Drug therapy for obstructive sleep apnoea in adults
Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea
Weight loss intervention through lifestyle modification or pharmacotherapy for obstructive sleep apnoea in adults (protocol stage)
Lifestyle modification (3)
Positional therapy for obstructive sleep apnoea
Lifestyle modification for obstructive sleep apnoea
Weight loss intervention through lifestyle modification or pharmacotherapy for obstructive sleep apnoea in adults (protocol stage)
Physical therapy (4)
Positional therapy for obstructive sleep apnoea
Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea
Respiratory muscle training for obstructive sleep apnoea (protocol stage)
Weight loss intervention through lifestyle modification or pharmacotherapy for obstructive sleep apnoea in adults (protocol stage)
Surgery (4)
Oral appliances for obstructive sleep apnoea (protocol stage)
Surgery for obstructive sleep apnoea in adults
Tonsillectomy versus tonsillotomy for obstructive sleep-disordered breathing in children
Tonsillectomy with or without adenoidectomy versus no surgery for obstructive sleep-disordered breathing in children
Oxygen (0)
Stridor, post-extubation (1)
Corticosteroids for the prevention and treatment of post-extubation stridor in neonates, children and adults
Tracheomalacia (1)
Interventions for primary (intrinsic) tracheomalacia in children
Wheeze (6)
Anticholinergic drugs for wheeze in children under the age of two years
Inhaled steroids for episodic viral wheeze of childhood
Ketotifen alone or as additional medication for long-term control of asthma and wheeze in children
Parent-initiated oral corticosteroid therapy for intermittent wheezing illnesses in children
Short acting beta2-agonists for recurrent wheeze in children under two years of age
Leukotriene receptor antagonists as maintenance and intermittent therapy for episodic viral wheeze in children